Sahel et al, Nature Medicine and StreetLab/Institut de la Vision
A man who is blind has had glimmers of vision restored thanks to a high-tech treatment using optogenetics, which involves genetically altering nerve cells so they respond to light.
French firm GenSight Biologics has published results showing that the first recipient of its treatment can recognise different objects in lab tests. “It’s exciting to see the first publication on human optogenetics,” says Ed Boyden at the Massachusetts Institute of Technology in Boston, a co-inventor of optogenetics.
Advertisement
Optogenetics has become a widely used lab tool, because it allows precision control over brain cells by altering them so they fire in response to light. It has led to many discoveries about the brain when used in animals – but is thought to have limited medical potential for treating brain disorders in people, because getting light inside the head requires implanting a fibre optic cable.
Logran que un ciego total vea por primera vez en su vida
clarin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clarin.com Daily Mail and Mail on Sunday newspapers.
Fluorescent proteins light up science by making the invisible visible
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Does Synchronizing Brain Waves Bring Harmony?
alzforum.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzforum.org Daily Mail and Mail on Sunday newspapers.
MedCity News
Cognito looks to light, sound for potential Alzheimer’s treatment
Digital health startup Cognito shared results of a Phase 2 trial of its device, intended to treat Alzheimer’s disease using gamma frequency light and sound. Based on the results, it plans to launch a pivotal study of the treatment.
Shares0
In a sea of failed Alzheimer’s treatments, a digital health startup is hoping to find answers in a noninvasive treatment using light and sound.
Cognito was founded by MIT Professors Li-Huei Tsai and Ed Boyden. The company was spun out of research where they found they could reduce amyloid plaques in mice by exposing them to light flickering at a certain frequency. Now, they’re seeing if the treatment holds promise for Alzheimer’s patients.